Breaking Finance News

Needham announced Exelixis Inc (NDAQ:EXEL), bumping up its stock price target to $30.00 today

In a report released on 9/12/2017 Needham increased the stock price target of Exelixis Inc (NDAQ:EXEL) from $28.00 to $30.00 reporting a possible upside of 0.11%.

Previously on Friday July 14, 2017, Suntrust Robinson reported on Exelixis Inc (NDAQ:EXEL) increased the target price from $0.00 to $33.00. At the time, this indicated a possible upside of 0.24%.

Just yesterday Exelixis Inc (NDAQ:EXEL) traded 1.04% higher at $26.95. Exelixis Inc’s 50-day moving average is $27.13 and its 200-day moving average is $23.24. The last closing price is up 12.90% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 4,520,959 shares of EXEL traded hands, up from an average trading volume of 4,105,680

Recent Performance Chart

Exelixis Inc (NDAQ:EXEL)

Exelixis Inc has 52 week low of $10.04 and a 52 week high of $29.50 with a PE ratio of 132.53 and has a market capitalization of $0.

In addition to Needham reporting its stock price target, a total of 3 brokers have issued a research note on the company. The average stock price target is $7.00 with 3 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

Brief Synopsis On Exelixis Inc (NDAQ:EXEL)

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *